Report cover image

Strategic Intelligence: Orphan Designated Drugs

Publisher GlobalData
Published Aug 28, 2024
Length 50 Pages
SKU # GBDT19567275

Description

Strategic Intelligence: Orphan Designated Drugs

Summary

This report consolidates GlobalData’s latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the orphan designated drugs in pharma space, as well as providing insights into the leading players and future challengers across the value chain, and providing insights into key drugs and markets from GlobalData’s Pharma Intelligence Center. Additionally, this report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future.

Due to the unmet medical demands of many rare diseases around the world, the number of orphan designated drugs (ODD) by regulatory agencies such as the FDA and EMA has increased in recent years. This has arisen from international recognition of the significant number of people that rare diseases affect daily, paired with limited therapeutic options and low patient populations.

As a result, a wide variety of pharmaceutical companies are expanding their orphan drug portfolio through co-development partnerships and collaborations, innovative means of personalized and precision therapy, as well as receiving financial and legal support from regulatory bodies to meet this unmet medical need.

Scope
  • A dedicated report examining the pivotal healthcare, technological, macroeconomic, and regulatory trends shaping the orphan designated drugs field in pharma landscape.
  • This report also provides an in-depth analysis of how these trends are poised to either accelerate progress or create obstacles for the growth of the orphan designated drugs market.
Reasons to Buy
  • Understand the key trends accelerating or hindering the orphan designated drugs in pharma space.

Table of Contents

50 Pages
Executive Summary
Players
Thematic Briefing
Trends
Healthcare trends
Technology trends
Macroeconomic trends
Regulatory trends
Industry Analysis
Market size and growth forecasts
Case studies
Vyxeos Combination for IV Injection Receives Orphan Drug Designation for the Treatment of High-Risk AML in Japan
Panavance Therapeutics Awarded ODD for its Pancreatic Cancer Treatment
PhamAust Limited Reveals Encouraging Results for Monepantel
Can-Fite Biopharma’s Namodenoson Demonstrating Anti-cancer and Protective Effects in the Liver
Signals
M&A trends
Strategic partnerships
Funding
Social media trends
Value Chain
Drug discovery and development
Clinical trials
Manufacturing
Patient access
Companies
Public companies
Private companies
Sector Scorecards
Clinical trials scorecard
Who’s who
Thematic screen
Valuation screen
Risk screen
Abbreviations
Bibliography
Further Reading
GlobalData reports
Our Thematic Research Methodology
About GlobalData
Contact Us
List of Tables
Table 1: Healthcare trends
Table 2: Technology trends
Table 3: Macroeconomic trends
Table 4: Regulatory trends
Table 5: M&A trends
Table 6: Strategic partnerships
Table 7: Funding
Table 8: Public companies
Table 9: Private companies
Table 10: Abbreviations
Table 11: GlobalData reports
Table 12: Thematic Scores
List of Figures
Figure 1: Examples of players in orphan designated drugs and where they sit in the value chain
Figure 2: Global patient-based forecast for orphan designated drugs, 2018–28
Figure 3: Global patient-based forecast for orphan designated drugs by highest generating drugs and indications, 2028
Figure 4: Social media discussions related to orphan designated drugs since 2021
Figure 5: Word cloud with trends related to orphan designated drugs social media discussions
Figure 6: Examples of popular posts related to orphan designated drugs
Figure 7: The orphan designated drugs value chain
Figure 8: Examples of drug discovery and development providers in orphan designated drugs
Figure 9: Examples of clinical trial developers in orphan designated drugs
Figure 10: Examples of manufacturing providers in orphan designated drugs
Figure 11: Examples of patient access developers in orphan designated drugs
Figure 12: Who does what in the orphan designated drugs space?
Figure 13: Thematic screen
Figure 14: Valuation screen
Figure 15: Risk screen
Figure 16: Our five-step approach for generating a sector scorecard

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us